Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
Clinical trial NCT05517330 · COMPLETED
Trial details
- NCT number
- NCT05517330
- Sponsor
- West China Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-19
- Primary completion
- 2023-12-31
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.